Disease progression of alpha-mannosidosis and impact on patients and carers – a UK natural history survey

dc.contributor.authorAdam, Jacqueline
dc.contributor.authorMalone, Rachel
dc.contributor.authorLloyd, Sioned
dc.contributor.authorLee, Jennifer
dc.contributor.authorHendriksz, Christian J.
dc.contributor.authorRamaswami, Uma
dc.date.accessioned2020-08-12T13:37:09Z
dc.date.available2020-08-12T13:37:09Z
dc.date.issued2019-09
dc.descriptionSupplementary Material 1: EQ-5D-5L domains walking ability resultsen_ZA
dc.descriptionSupplementary Material 2: Patient questionnairesen_ZA
dc.description.abstractINTRODUCTION: Alpha-mannosidosis is an ultra-rare lysosomal storage disorder resulting from the deficient activity of lysosomal alpha-mannosidase. Alpha-mannosidosis presents as a highly heterogenous condition with large variations in symptom severity and disease progression rates. Quantitative and qualitative data for alphamannosidosis patients and their caregivers provide important insights into their daily experiences. METHODS: A survey of nine alpha-mannosidosis patients was carried out in the UK between August 2017 and January 2018. Patient demographics, health-related quality of life (HRQoL), and qualitative data from patients and carers relating to clinical characteristics and impact of the disease and treatment were analysed. RESULTS: At the time of survey completion, patient age ranged from 7 to 37 years. Five patients were described as ‘walking unassisted’, one as ‘walking with assistance’, one as ‘wheelchair-dependent’, and two as ‘severely immobile’. In addition to best supportive care, three patients had received haematopoietic stem cell transplantation (HSCT) and one had received velmanase alfa enzyme replacement therapy (ERT). Patient HRQoL results for the EQ-5D-5 L questionnaire and the Health Utilities Index-3 showed that patients with more severe ambulatory health states reported lower utility values than patients who were more mobile. Patients who received HSCT or ERT experienced improved HRQoL. Carer HRQoL results for the Hospital Anxiety and Depression Scale and Caregiver Strain Index demonstrated that carers experience high levels of stress and anxiety from their caregiving responsibilities. CONCLUSIONS: This survey confirmed the heterogeneity of alpha-mannosidosis and the large impact of the disease and treatment on patients, carers, and families. Early diagnosis and access to treatment offers the best chance of slowing the disease progression and may provide some relief to patients and carers.en_ZA
dc.description.departmentPaediatrics and Child Healthen_ZA
dc.description.librarianpm2020en_ZA
dc.description.sponsorshipChiesi Limiteden_ZA
dc.description.urihttp://www.elsevier.com/locate/ymgmren_ZA
dc.identifier.citationAdam, J., Malone, R., Lloyd, S. et al. 2019, 'Disease progression of alpha-mannosidosis and impact on patients and carers – a UK natural history survey', Molecular Genetics and Metabolism Reports, vol. 20, art. 100480, pp. 1-9.en_ZA
dc.identifier.issn2214-4269 (online)
dc.identifier.other10.1016/j.ymgmr.2019.100480
dc.identifier.urihttp://hdl.handle.net/2263/75668
dc.language.isoenen_ZA
dc.publisherElsevieren_ZA
dc.rights© 2019 The Authors. Published by Elsevier Inc. This article is published under the CC BY license.en_ZA
dc.subjectAlpha-mannosidosisen_ZA
dc.subjectLysosomal storage disorderen_ZA
dc.subjectVelmanase alfaen_ZA
dc.subjectQuality of lifeen_ZA
dc.subjectHaematopoietic stem cell transplantation (HSCT)en_ZA
dc.subjectEnzyme replacement therapy (ERT)en_ZA
dc.subjectHealth-related quality of life (HRQoL)en_ZA
dc.titleDisease progression of alpha-mannosidosis and impact on patients and carers – a UK natural history surveyen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 3 of 3
Loading...
Thumbnail Image
Name:
Adam_Disease_2019.pdf
Size:
584.79 KB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Adam_DiseaseSuppl1_2019.pdf
Size:
77.7 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Material 1
Loading...
Thumbnail Image
Name:
Adam_DiseaseSuppl2_2019.pdf
Size:
1.48 MB
Format:
Adobe Portable Document Format
Description:
Supplementary Material 2

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: